v3.25.4
Consolidated Statements of Changes in Stockholders’ Equity - USD ($)
$ in Thousands
Total
Total Equity Attributable to Common Stockholders
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2022     205,664,690        
Beginning balance at Dec. 31, 2022 $ 378,816 $ 340,777 $ 20 $ 3,906,491 $ (1,251) $ (3,564,483) $ 38,039
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of restricted stock awards (in shares)     4,160,416        
ESPP purchase (in shares)     875,695        
ESPP purchase 13,363 13,363   13,363      
Exercise of stock options (in shares)     525,031        
Exercise of stock options 3,582 3,582   3,582      
Stock-based compensation 87,076 87,076   87,076      
Contributions from noncontrolling interest (Note 12) 6,979           6,979
Conversion of securities (in shares)     13,491,701        
Conversion of securities 310,485 310,485 $ 1 310,484      
Foreign currency translation adjustment (430) (436)     (436)   6
Distributions and payments to noncontrolling interest (Note 11) (2,265)           (2,265)
Buyout of noncontrolling interest (Note 11) (6,864) 11,482   11,482     (18,346)
Derecognition of the pre-modification forward contract fair value (Note 17) 76,242 76,242   76,242      
Equity component of redeemable convertible preferred stock (Note 17) 16,145 16,145   16,145      
Purchase of capped call related to convertible notes (Note 8) (54,522) (54,522)   (54,522)      
Net (loss) income (307,937) (302,116)       (302,116) (5,821)
Ending balance (in shares) at Dec. 31, 2023     224,717,533        
Ending balance at Dec. 31, 2023 520,670 502,078 $ 21 4,370,343 (1,687) (3,866,599) 18,592
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of restricted stock awards (in shares)     3,067,129        
Issuance of restricted stock awards 2 2 $ 2        
ESPP purchase (in shares)     1,049,955        
ESPP purchase $ 10,344 10,344   10,344      
Exercise of stock options (in shares) 307,857   307,857        
Exercise of stock options $ 2,021 2,021   2,021      
Stock-based compensation 79,951 79,951   79,951      
Contributions from noncontrolling interest (Note 12) 3,958           3,958
Accrued dividend (1,620) (1,620)       (1,620)  
Legal reserve 147 147       147  
Subsidiary liquidation (319) (319)       (319)  
Foreign currency translation adjustment (2,735) (906)     (906)   (1,829)
Net (loss) income (27,203) (29,227)       (29,227) 2,024
Ending balance (in shares) at Dec. 31, 2024     229,142,474        
Ending balance at Dec. 31, 2024 585,216 562,471 $ 23 4,462,659 (2,593) (3,897,618) 22,745
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of restricted stock awards (in shares)     5,184,791        
Issuance of restricted stock awards 1 1 $ 1        
ESPP purchase (in shares)     1,073,929        
ESPP purchase $ 11,354 11,354   11,354      
Exercise of stock options (in shares) 2,098,714   2,098,714        
Exercise of stock options $ 47,768 47,768   47,768      
Stock-based compensation 140,222 140,222   140,222      
Accrued dividend (1,024) (1,024)       (1,024)  
Legal reserve 93 93       93  
Premium on convertible debt (Note 8) 28,247 28,247   28,247      
Conversion of securities (in shares)     137,606        
Conversion of securities 2,230 2,230   2,230      
Induced conversion of convertible notes (Note 8) (in shares)     42,407,945        
Induced conversion of convertible notes (Note 8) 47,542 47,542 $ 4 47,538      
Share-based consideration payable to customer’s customer (Note 3) 15,947 15,947   15,947      
Foreign currency translation adjustment 2,507 2,224     2,224   283
Net (loss) income (87,140) (88,434)       (88,434) 1,294
Ending balance (in shares) at Dec. 31, 2025     280,045,459        
Ending balance at Dec. 31, 2025 $ 792,963 $ 768,641 $ 28 $ 4,755,965 $ (369) $ (3,986,983) $ 24,322